Tags

Type your tag names separated by a space and hit enter

Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
World J Gastroenterol. 2015 Apr 21; 21(15):4696-706.WJ

Abstract

AIM

To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein (AFP) level of chronic hepatitis C patients.

METHODS

A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122). The relationship between virological response and the change in the serum AFP level from baseline to 24 wk after the end of treatment was examined.

RESULTS

No significant difference in mean baseline AFP level was found between the triple and dual therapy groups (8.8 ng/mL vs 7.8 ng/mL). Triple therapy produced significant declines in the AFP level in sustained virological response (SVR) and non-SVR patients (7.8 ng/mL at baseline to 3.5 ng/mL at 24 wk after the end of treatment, P < 0.001 and 14.3 ng/mL to 9.5 ng/mL, P = 0.004, respectively). In contrast, dual therapy resulted in a significant decline in AFP level only in SVR patients (4.7 ng/mL to 2.8 ng/mL, P < 0.001), but not in non-SVR patients (10.2 ng/mL to 10.1 ng/mL). Among patients with a high-baseline AFP level (≥ 10 ng/mL), the decline in the AFP level was significantly higher in the triple therapy than in the dual therapy group (15.9 ng/mL vs 1.6 ng/mL, P = 0.037).

CONCLUSION

Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level.

Authors+Show Affiliations

Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

25914481

Citation

Takayama, Koji, et al. "Direct-acting Antiviral-based Triple Therapy On Alpha-fetoprotein Level in Chronic Hepatitis C Patients." World Journal of Gastroenterology, vol. 21, no. 15, 2015, pp. 4696-706.
Takayama K, Furusyo N, Ogawa E, et al. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol. 2015;21(15):4696-706.
Takayama, K., Furusyo, N., Ogawa, E., Ikezaki, H., Shimizu, M., Murata, M., & Hayashi, J. (2015). Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World Journal of Gastroenterology, 21(15), 4696-706. https://doi.org/10.3748/wjg.v21.i15.4696
Takayama K, et al. Direct-acting Antiviral-based Triple Therapy On Alpha-fetoprotein Level in Chronic Hepatitis C Patients. World J Gastroenterol. 2015 Apr 21;21(15):4696-706. PubMed PMID: 25914481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. AU - Takayama,Koji, AU - Furusyo,Norihiro, AU - Ogawa,Eiichi, AU - Ikezaki,Hiroaki, AU - Shimizu,Motohiro, AU - Murata,Masayuki, AU - Hayashi,Jun, PY - 2014/08/28/received PY - 2014/12/09/revised PY - 2015/01/21/accepted PY - 2015/4/28/entrez PY - 2015/4/29/pubmed PY - 2016/2/4/medline KW - Chronic hepatitis C KW - Direct-acting antiviral agents KW - Hepatocellular carcinoma KW - Serum alpha-fetoprotein KW - Telaprevir SP - 4696 EP - 706 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 21 IS - 15 N2 - AIM: To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein (AFP) level of chronic hepatitis C patients. METHODS: A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122). The relationship between virological response and the change in the serum AFP level from baseline to 24 wk after the end of treatment was examined. RESULTS: No significant difference in mean baseline AFP level was found between the triple and dual therapy groups (8.8 ng/mL vs 7.8 ng/mL). Triple therapy produced significant declines in the AFP level in sustained virological response (SVR) and non-SVR patients (7.8 ng/mL at baseline to 3.5 ng/mL at 24 wk after the end of treatment, P < 0.001 and 14.3 ng/mL to 9.5 ng/mL, P = 0.004, respectively). In contrast, dual therapy resulted in a significant decline in AFP level only in SVR patients (4.7 ng/mL to 2.8 ng/mL, P < 0.001), but not in non-SVR patients (10.2 ng/mL to 10.1 ng/mL). Among patients with a high-baseline AFP level (≥ 10 ng/mL), the decline in the AFP level was significantly higher in the triple therapy than in the dual therapy group (15.9 ng/mL vs 1.6 ng/mL, P = 0.037). CONCLUSION: Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/25914481/Direct_acting_antiviral_based_triple_therapy_on_alpha_fetoprotein_level_in_chronic_hepatitis_C_patients_ L2 - http://www.wjgnet.com/1007-9327/full/v21/i15/4696.htm DB - PRIME DP - Unbound Medicine ER -